Abstract 804
Background
A decrease lymphocyte to monocyte ratio (LMR) has been reported to be related with worsen prognosis for certain hematologic and solid malignancies. Also pretreatment LMR is associated with the prognosis of patients with breast cancer. However, relationship between treatment-related low LMR and prognostic impact has not well been investigated in breast cancer. The purpose of this study is to evaluate the relationship between radiotherapy (RT)-induced low LMR and recurrence in patients with breast cancer.
Methods
We retrospectively reviewed 1,735 patients with stage I to III breast cancer treated with breast conserving surgery (BCS) and adjuvant RT at Gangnam Severance Hospital and Severance Hospital from January 2006 to 2016 December. The values of LMR were calculated at baseline (A1), before the first RT administration (A2) and before the last RT administration (A3). The reference point of RT-induced low LMR was defined as ≤ 2.6 used in other studies. The recurrence-free survival (RFS) was compared according to RT-induced LMR.
Results
We retrospectively reviewed 1,735 patients with stage I to III breast cancer treated with breast conserving surgery (BCS) and adjuvant RT at Gangnam Severance Hospital and Severance Hospital from January 2006 to 2016 December. The values of LMR were calculated at baseline (A1), before the first RT administration (A2) and before the last RT administration (A3). The reference point of RT-induced low LMR was defined as ≤ 2.6 used in other studies. The recurrence-free survival (RFS) was compared according to RT-induced LMR.
Conclusions
We demonstrated that RT-induced low LMR is a poor prognostic factor for patients with BCS and adjuvant RT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1694 - Pembrolizumab (pembro) Plus mFOLFOX or FOLFIRI in Patients With Metastatic Colorectal Cancer (mCRC): KEYNOTE-651 Cohorts B and D
Presenter: Richard Kim
Session: Poster Display session 2
Resources:
Abstract
908 - Romidepsin (FK228) Regulates the Expression of the Immune Checkpoint Ligand PD-L1 and Exerts Synergistic Anti-Tumor Activity with an Anti-PD-1 Antibody in Colon Cancer
Presenter: Hui Li
Session: Poster Display session 2
Resources:
Abstract
3127 - Prognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first line chemotherapy.
Presenter: Zafeiris Zafeiriou
Session: Poster Display session 2
Resources:
Abstract
5416 - The SAFFO study: Sex-related prognostic role And cut-oFf deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer
Presenter: Camilla Lisanti
Session: Poster Display session 2
Resources:
Abstract
2518 - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumors of epithelial origin: analysis of the metastatic colorectal cancer patients in the dose escalation phase
Presenter: Marwan Fakih
Session: Poster Display session 2
Resources:
Abstract
4000 - Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Presenter: Niels Halama
Session: Poster Display session 2
Resources:
Abstract
2223 - Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer
Presenter: Wataru Okamoto
Session: Poster Display session 2
Resources:
Abstract
2569 - Phase II trial of Trametinib (T) and Panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)
Presenter: Kanan Alshammari
Session: Poster Display session 2
Resources:
Abstract
5402 - Microsatellite instability and immunogenicity in colorectal cancer – do resident memory Tcells (Trm) play a role in colorectal cancer
Presenter: Wei Toh
Session: Poster Display session 2
Resources:
Abstract
5472 - Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Camilla Qvortrup
Session: Poster Display session 2
Resources:
Abstract